At Shattuck Labs, we are pioneering a new class of dual function fusion proteins to create novel therapeutics for patients with cancer and autoimmune disease.

Shattuck was founded in 2016 with the goal of building a fully integrated biotechnology company that creates novel therapeutics for the treatment of cancer and autoimmune disease. At the core of that vision was creating a company that brings together leading scientists, drug manufacturers, physicians, and other professionals to challenge conventional thinking and develop transformational medicines that measurably improve the lives of our patients.

One of the truly differentiating aspects of Shattuck has been the novelty of our proprietary Agonist Redirected Checkpoint (ARC) platform technology. Combining a strong technological foundation with deep professional expertise has allowed us to deliver on our broader corporate mission.  Demonstrating our sense of urgency, we were able to bring our first compound to the clinic within two years of founding the company.

With over 400 ARC compounds produced to date, Shattuck’s research and discovery engine has yielded enormous results. Our discovery production is a cornerstone of all that we do, and we have invested heavily in understanding the science behind all of our compounds. As a result of the significant investment in our platform, we are able to move compounds from bench to clinic in fewer than 18 months, well ahead of industry-standard timelines.

Our lead product candidate, SL-172154, is in global clinical trials, treating cancer patients with a high unmet need. Our constant pursuit of excellence continues to drive us to build a company at the helm of providing truly breakthrough medicines for patients in need.

Our Origins

A message from Josiah Hornblower, Co-founder, CEO from 2016-2020

Shattuck Labs was born out of deep friendship, a mutual passion for science, and a radical goal of redesigning cancer medicines to improve human health. My co-founder Taylor Schreiber and I became friends a few years after college, when I was pursuing a finance career in New York and he was working in a research lab in Boston. We initially bonded through our common high-school experience at St. Paul’s School in Concord, NH, where I graduated several years before him. Our friendship evolved during Taylor’s MD/Ph.D. training, when we would have long conversations about cutting-edge technologies that could positively change the world.

Eventually, our divergent career paths merged through a series of collaborative biotechnology ventures. Each chapter in this odyssey of building biotech companies has informed our present vision of what our company should be. Shattuck Labs was established in May 2016 and named after George Shattuck, a young, visionary medical doctor who founded our high school in 1856. His legacy gave me and Taylor a common bond and experience that ultimately brought forth the company we have built today. We feel very privileged to see Shattuck grow, evolve, and succeed with the help of our amazing colleagues. In early 2020 Taylor took over as CEO, and our partnership continues. Shattuck is now at the nexus of recent advances in the targets that benefit cancer patients, as well as the tools required to engage those targets. I could not be more excited to help our team write the next chapter in Shattuck’s story.

Talor and Josiah non a mountain top

Mission & Vision

Our vision is to build incredible medicines off the beaten path, by challenging ourselves to think differently.

We work with a sense of urgency, focused on scientific excellence and thoughtful stewardship of resources, to translate innovative ideas into medicines that improve the lives of patients with serious diseases.

Shattuck Lab



Board of Directors

George Golumbeski, PhD

Chairman of the Board and Former Executive Vice President of Business Development for Celgene

George Golumbeski has more than 30 years of experience in the biotechnology industry. He has a long history of forging collaborations with companies engaged in “cutting edge” science.  Currently he is dedicated to working to develop young companies. He is a partner at DROIA Ventures. He currently serves on the Board of Directors of Carrick Therapeutics, Sage Therapeutics, and MorphoSys. George was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a bachelor’s degree in biology from the University of Virginia

Close X

Helen M. Boudreau

Former COO of the Bill & Melinda Gates Medical Research Institute

Helen has 30 years of experience across the biotech, pharmaceuticals, consulting and banking industries. Helen was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech focused on diseases that cause mortality, poverty and inequality in low- and middle-income countries. Previously, she served as CFO for public and private biotechs, and served in senior finance roles at Novartis and Pfizer, including CFO for Novartis Global Oncology. Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, and is also on the boards of two private biotech companies. Helen earned a BA in Economics, summa cum laude, from the University of Maryland, and an MBA from the Darden Graduate School of Business at the University of Virginia.

Close X

Tyler Brous

Portfolio Manager, Lennox Capital Partners, LP

Tyler is Managing Director and Portfolio Manager of Lennox Capital Partners, LP, a special situations and value-oriented investment company active in public and private equity. While at Lennox, Tyler spent over a year working at Arog Pharmaceuticals as the acting CFO, leading their capital markets and business development efforts. Prior to joining Lennox, Tyler worked as a senior analyst at YX Funds, a short-only hedge fund in Dallas. In addition, Tyler started his career in the M&A group at Citigroup in New York. Tyler holds a B.S. in Finance and Business Honors from the University of Texas, where he graduated Summa Cum Laude.

Close X

Carrie Brownstein, MD

Former CMO of Zentalis Pharmaceuticals

Carrie Brownstein brings 2 decades of experience in the field of oncology and other therapeutic areas addressing high unmet medical needs across biotech, and large and small pharma. Carrie served as the Chief Medical Officer (CMO) of Zentalis Pharmaceuticals, where she led a team responsible for the global development of a portfolio of small molecules targeting fundamental pathways in cancers, and as CMO of Cellectis Inc. a clinical stage biotech company, where she was responsible for advancing a portfolio of novel, first in class allogeneic CAR-T cell therapies for patients with hematologic malignancies. Previously, she held several senior leadership positions including Vice President of Global Clinical Research and Development (R&D), Therapeutic Area Head for Myeloid Diseases at Celgene, where she was responsible for the global clinical development and subsequent global regulatory approvals and launches of groundbreaking first in class products including REBLOZYL® for MDS and beta-thalassemia, INREBIC® for myelofibrosis, and IDHIFA® and ONUREG® for AML.  Prior to Celgene, Carrie held positions of increasing responsibility at Regeneron Pharmaceuticals and Hoffman-La Roche. Carrie is a graduate of Memorial Sloan Kettering Cancer Center’s pediatric hematology-oncology fellowship program and completed her internship and residency training at Columbia Presbyterian Medical Center in New York.  Dr. Brownstein practiced pediatric hematology and oncology at New York Presbyterian Columbia University and Mount Sinai Medical Center prior to joining industry. Dr. Brownstein received her M.D. from Tufts University School of Medicine and received her A.B. in Psychology from the University of Michigan.

Close X

Neil Gibson, PhD

Chief Scientific Officer, Biologics, COI Pharma

Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, BioAtla; chief scientific officer, Regulus Therapeutics; chief scientific officer and oncology therapeutic area head, Pfizer Oncology; and chief scientific officer, OSI Pharmaceuticals. While at Pfizer, Neil was also a member of the Pfizer Oncology Business Unit Executive team. Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus he was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101. Neil has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, he has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.

Close X

Michael Lee

Co-founder, Redmile Group, LLC

Mr. Lee is a co-founder and portfolio manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and Prudential Equity Group. Mike holds a B.S. in Molecular and Cellular Biology from the University of Arizona.

Close X

Kate Sasser, PhD

Chief Scientific Officer of Tempus

Dr. Kate Sasser is the Chief Scientific Officer of Tempus. Dr. Sasser brings over 25 years of experience in translational research and precision medicine in biological sciences across academia and the pharmaceutical and biotech industry. Prior to Tempus, she led the translational research, precision medicine, and R&D operations organizations within Genmab A/S, a biotech company focused on developing transformative antibody therapeutics as medicine. She also led translational research for oncology at Johnson and Johnson Innovative Medicine (formerly Janssen Pharmaceuticals Companies). Dr. Sasser holds a Ph.D. in Integrated Biomedical Sciences from the Ohio State University as well as a B.S. from Oregon State University.

Close X

Taylor H. Schreiber, MD, PhD

Chief Executive Officer and Co-founder

Taylor is a co-founder of Shattuck Labs and currently serves as Chief Executive Officer and a member of the Board of Directors. Before his appointment as CEO in January 2020, Taylor served as the company’s Chief Scientific Officer. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. Taylor was also the co-inventor of Pelican Therapeutics ‘s TNFRSF25 agonist technology where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, he received the best overall research award at the National Student Research Forum, and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research. Taylor received both his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.

Close X

Clay Siegall

President, Chief Executive Officer and Chairman of the Board of Immunome, Inc.

Dr. Clay Siegall is the President, Chief Executive Officer and Chairman of the Board of Immunome, Inc. (Nasdaq: IMNM). With a distinguished career in leadership and drug development, he has significantly contributed to the pharmaceutical industry, including spearheading the establishment of antibody-drug conjugates as a backbone of cancer therapy in many indications. Previously, Dr. Siegall held the positions of Chief Executive Officer, President, and Chairman of the Board at Seagen Inc. (formerly Seattle Genetics, Inc.). He was the founder of Seattle Genetics, established in 1998, where he guided the company to prominence as a pharmaceutical leader, particularly in the development of antibody-drug conjugates for cancer therapy. Prior to founding Seattle Genetics, Dr. Siegall held numerous leadership positions at Bristol Myers Squibb’s Pharmaceutical Research Institute and the National Cancer Institute. Dr. Siegall holds a Ph.D. in Genetics from George Washington University as well as a B.S. in Zoology from the University of Maryland.

Close X

Advisory Board

Johann De Bono, MD, PhD

The Institute of Cancer Research

Aurélien Marabelle MD, PhD

Institut Gustave Roussy

Ignacio Melero, MD, PhD

Clinica Universidad de Navarra

Drew Pardoll, MD, PhD

Johns Hopkins University School of Medicine

Kurt Schalper MD, PhD

Yale School of Medicine
ct sl here 5: